Cellectis Announces the execution of the Subsequent Investment Agreement with AstraZeneca
November 15, 2023 02:30 ET
|
Cellectis Inc.
Execution of binding subsequent investment agreement regarding contemplated additional equity investment of $140M by AstraZeneca, previously announced on November 1, 2023.Extraordinary shareholders’...
Cellectis publie ses résultats financiers du troisième trimestre 2023
November 06, 2023 16:30 ET
|
Cellectis Inc.
• Signature d’une Collaboration Stratégique et un Accord d'Investissement Avec AstraZeneca Cellectis présentera des résultats actualisés de l'essai de phase I BALLI-01 (évaluant UCART22 chez des...
Cellectis Reports Financial Results for Third Quarter and First Nine Months 2023
November 06, 2023 16:30 ET
|
Cellectis Inc.
• Strategic Collaboration and Investment Agreements signed with AstraZeneca Updated results of the Phase I BALLI-01 Trial evaluating UCART22 in r/r B-cell ALL and preliminary results of the Phase I...
Information mensuelle relative au nombre total des droits de vote et d’actions composant le capital social
November 03, 2023 16:30 ET
|
Cellectis Inc.
(Article 223-16 du Règlement Général de l’Autorité des Marchés Financiers) PARIS, 03 nov. 2023 (GLOBE NEWSWIRE) -- Place de cotation : Euronext Growth Code ISIN : FR0010425595DateNombre...
Monthly information on share capital and company voting rights
November 03, 2023 16:30 ET
|
Cellectis Inc.
(Article 223-16 of General Regulation of the French financial markets authority) PARIS, Nov. 03, 2023 (GLOBE NEWSWIRE) -- Listing market: Euronext Growth ISIN code: FR0010425595 DateTotal number...
Cellectis présentera des données préliminaires de l’essai NATHALI_01 et des résultats actualisés de l’essai BALLI_01 lors de la 65ème réunion annuelle de la American Society of Hematology (ASH)
November 02, 2023 16:30 ET
|
Cellectis Inc.
NEW YORK, 02 nov. 2023 (GLOBE NEWSWIRE) -- Cellectis (Euronext Growth: ALCLS - Nasdaq: CLLS), société de biotechnologie de stade clinique, qui utilise sa technologie pionnière d'édition de génome...
Cellectis to Present Preliminary Results of NATHALI_01 and Updated Results of the BALLI_01 Phases I Trials at the American Society of Hematology (ASH) 65th Annual Meeting
November 02, 2023 16:30 ET
|
Cellectis Inc.
NEW YORK, Nov. 02, 2023 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to...
Cellectis présentera ses résultats financiers du troisième trimestre 2023 le 6 novembre 2023
November 01, 2023 16:30 ET
|
Cellectis Inc.
NEW YORK, 01 nov. 2023 (GLOBE NEWSWIRE) -- Cellectis (Euronext Growth: ALCLS - Nasdaq: CLLS), société de biotechnologie de stade clinique qui utilise sa technologie pionnière d’édition du génome...
Cellectis to Report Third Quarter 2023 Financial Results on November 6, 2023
November 01, 2023 16:30 ET
|
Cellectis Inc.
NEW YORK, Nov. 01, 2023 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS- NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to...
Cellectis Announces Strategic Collaboration and Investment Agreements with AstraZeneca
November 01, 2023 03:00 ET
|
Cellectis Inc.
Collaboration leverages Cellectis’ gene editing technologies and manufacturing capabilities to develop up to 10 novel cell & gene therapy candidate productsCellectis to receive up to $245M in cash...